Loading
Search
▼ Nikkei Posts Biggest Daily Drop In 3 Months On Renewed Fears Of Global Slowdown
- Category:Other
TOKYO (Reuters) — Nikkei posted the biggest daily drop in three months on Monday as investors moved into bonds and other assets perceived as safe amid renewed fears of a global economic slowdown.
The Nikkei share average stumbled 3 percent to 20,977.11, the lowest since mid-February and the steepest daily fall since late December.
The broader Topix fell 2.5 percent to a two-week low of 1,577.41, with all of its 33 subsectors trading in negative territory.
On Friday, the spread between yields of U.S. three-month Treasury bills exceeded those of 10-year notes for the first time since 2007.
The inversion of the Treasury yield curve suggested the world’s largest economy could slide into recession and reignited fears of a deepening slowdown in the global economy.
Japanese insurers and banks, which seek higher yielding products such as U.S. bonds, sold off sharply on Monday, weighed down by the inversion of part of the U.S. yield curve.
Dai-ichi Life Holdings shed 3 percent, T&D Holdings was off 2.7 percent and Tokio Marine Holdings dropped 1.4 percent.
“Insurers react negatively as it becomes harder for them to manage assets,” said Eiji Kinouchi, chief technical analyst at Daiwa Securities.
Banks were also down, with Mitsubishi UFJ Financial Group 3 percent lower and Mizuho Financial Group off 1.1 percent.
Shares of companies that are relatively sensitive to the global economic outlook, such as factory automation equipment makers, lost ground on Monday.
Fanuc fell 3.8 percent while Keyence, an index heavyweight, gave up 1.2 percent.
Daiwa’s Kinouchi said firms that are relatively sensitive to the global outlook may rebound on robust stimulus in China — just as many had done after a sell off in December.
Index heavyweight SoftBank Group dropped 5 percent.
The drug sector remained in the spotlight, falling 3.9 percent.
Drug maker Eisai Co dived 19.83 percent to a daily-limit low of 6,065 yen after the company and its partner Biogen Inc said last week they had scrapped trials of an experimental Alzheimer’s drug.
The news weighed on other pharmaceutical names for a second session, with Astellas Pharmaceutical down 3.8 percent and Takeda Pharmaceutical giving up 2.5 percent.
The Nikkei share average stumbled 3 percent to 20,977.11, the lowest since mid-February and the steepest daily fall since late December.
The broader Topix fell 2.5 percent to a two-week low of 1,577.41, with all of its 33 subsectors trading in negative territory.
On Friday, the spread between yields of U.S. three-month Treasury bills exceeded those of 10-year notes for the first time since 2007.
The inversion of the Treasury yield curve suggested the world’s largest economy could slide into recession and reignited fears of a deepening slowdown in the global economy.
Japanese insurers and banks, which seek higher yielding products such as U.S. bonds, sold off sharply on Monday, weighed down by the inversion of part of the U.S. yield curve.
Dai-ichi Life Holdings shed 3 percent, T&D Holdings was off 2.7 percent and Tokio Marine Holdings dropped 1.4 percent.
“Insurers react negatively as it becomes harder for them to manage assets,” said Eiji Kinouchi, chief technical analyst at Daiwa Securities.
Banks were also down, with Mitsubishi UFJ Financial Group 3 percent lower and Mizuho Financial Group off 1.1 percent.
Shares of companies that are relatively sensitive to the global economic outlook, such as factory automation equipment makers, lost ground on Monday.
Fanuc fell 3.8 percent while Keyence, an index heavyweight, gave up 1.2 percent.
Daiwa’s Kinouchi said firms that are relatively sensitive to the global outlook may rebound on robust stimulus in China — just as many had done after a sell off in December.
Index heavyweight SoftBank Group dropped 5 percent.
The drug sector remained in the spotlight, falling 3.9 percent.
Drug maker Eisai Co dived 19.83 percent to a daily-limit low of 6,065 yen after the company and its partner Biogen Inc said last week they had scrapped trials of an experimental Alzheimer’s drug.
The news weighed on other pharmaceutical names for a second session, with Astellas Pharmaceutical down 3.8 percent and Takeda Pharmaceutical giving up 2.5 percent.
- March 26, 2019
- Comment (0)
- Trackback(0)